We are pleased to announce the successful DCP approval for Apremilast 10mg, 20mg, 30mg film-coated tablets.
Our product has been developed based on the reference brand Otezla Film-Coated Tablets, which is indicated in the treatment of Psoriatic Arthritis, Psoriasis and Behçet’s disease.
The brand sold at $4Bn globally in 2022, with a 3Y CAGR of 9% according to IQVIA.
As per public information as of today, we believe that Adalvo are the first to obtain DCP approval for Apremilast in Europe. Based on this progress, we are committed to being ready for launch on day-1, after the expiry of relevant IP rights.
This accomplishment reflects Adalvo's determination in advancing healthcare solutions and providing patients with access to cutting-edge treatments.
Partner up now!
At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
arni.baldursson@adalvo.com - Head of Global BD&L
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
marta.puig@adalvo.com - South Europe
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
bruno.alves@adalvo.com - Brazil
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
marc.nolasco@adalvo.com - Central and Western Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
Click on your preferred Business Partner and get in touch today!